The FDA has given Novocure (NSDQ:NVCR) the green light to bring the company’s Tumor Treating Fields tech into a pivotal Phase III pancreatic cancer trial.
The 556-patient study is designed to assess the safety and efficacy of Novocure’s TTFields combined with nab-paclitaxel and gemcitabine as a front-line treatment for unresectable locally-advanced pancreatic cancer.
Get the full story at our sister site, Drug Delivery Business News.
The post Novocure wins FDA nod for pivotal pancreatic cancer trial appeared first on MassDevice.